11 news items
HC Wainwright & Co. Reiterates Buy on Coherus BioSciences, Maintains $12 Price Target
CHRS
24 May 24
HC Wainwright & Co. analyst Douglas Tsao reiterates Coherus BioSciences (NASDAQ:CHRS) with a Buy and maintains $12 price target.
Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine receptor 8 (CCR8) Antibody, CHS-114, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
CHRS
23 May 24
antibody (mAb) that selectively and potently targets human CCR8 with no off-target binding. CCR8 is a G protein-coupled receptor (GPCR) that shows
Truist Securities Maintains Buy on Coherus BioSciences, Lowers Price Target to $7
CHRS
13 May 24
Truist Securities analyst Robyn Karnauskas maintains Coherus BioSciences (NASDAQ:CHRS) with a Buy and lowers the price target from $8 to $7.
HC Wainwright & Co. Maintains Buy on Coherus BioSciences, Raises Price Target to $12
CHRS
10 May 24
HC Wainwright & Co. analyst Douglas Tsao maintains Coherus BioSciences (NASDAQ:CHRS) with a Buy and raises the price target from $11 to $12.
Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update
CHRS
9 May 24
candidate targeting immune-suppressive mechanisms via the novel pathway ILT4 with a response from the FDA on our IND filing expected in the second quarter
61vo4zccooky1d7mqc9 estytpdgzvorgn
CHRS
8 Apr 24
by Coherus, CHS-1000 is a novel humanized Fc-modified IgG1 monoclonal antibody specifically targeting ILT4 (LILRB2). CHS-1000 is designed to overcome myeloid
y0gqd2jhdmrixj94q0v9ngsao3kth73h2zxbkm9xpbh
CHRS
20 Mar 24
HC Wainwright & Co. analyst Douglas Tsao maintains Coherus BioSciences (NASDAQ:CHRS) with a Buy and lowers the price target from $13 to $11.
axomtwps8tp9c061k8bwp28y8hhofi7b0rpfm7ryj3 rmd
CHRS
14 Mar 24
HC Wainwright & Co. analyst Douglas Tsao reiterates Coherus BioSciences (NASDAQ:CHRS) with a Buy and maintains $13 price target.
kqwlxt5tno2os504jrp0tbd6gl5p0d800e81o93b
CHRS
13 Mar 24
as national and regional commercial health plans.Early demand uptake tracking to expectations, with over 59 NPC targeted
zv2uax dvu
AADI
ACDC
ADCT
13 Mar 24
of $15.33 million.
• Target Hospitality (NASDAQ:TH) is expected
f5jn6nci
CHRS
4 Mar 24
; and a diversified immuno-oncology pipeline with drug candidates with distinctive targets designed to inhibit immune suppressive mechanisms in the tumor
- Prev
- 1
- Next